Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TELO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Chief Financial Officer departed the company effective June 6, 2026.
Telomir Pharmaceuticals CFO departs, replaced by fractional consultant at $6K/month
Filed June 8, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
medium
CFO Alan Weichselbaum departed effective June 6, 2026. Company states departure was not due to any disagreement on operations, policies, or practices.
Item 5.02 verify on EDGAR → -
medium
Andriy Mushak appointed fractional CFO at $6,000/month through consulting firm LMAM, rather than as full-time employee. Mushak is a CPA with 20+ years SEC reporting experience.
Item 5.02 verify on EDGAR → -
medium
Fractional CFO structure may signal cost management or transitional arrangement rather than permanent executive hire.
Item 5.02 verify on EDGAR →
Summary
Telomir Pharmaceuticals replaced its departing CFO with a fractional consultant arrangement, a notable shift in its finance leadership structure. Alan Weichselbaum exited the CFO role on June 6, with the company emphasizing his departure involved no disagreements. His replacement, Andriy Mushak, will serve as fractional CFO through his consulting firm LMAM at $6,000 monthly—substantially lower than typical CFO compensation and structured as a consulting relationship rather than direct employment.
The fractional arrangement suggests either aggressive cost management or a transitional solution while the company searches for permanent leadership. Mushak brings relevant credentials as a CPA with two decades of SEC reporting experience, but the part-time nature of the role raises questions about bandwidth for a public company's financial oversight. Investors should watch for signals about whether this is temporary bridge leadership or a longer-term cost structure, and monitor upcoming 10-Q filings for any financial reporting quality issues during the transition.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).
The board appointed Andriy Mushak as fractional CFO effective June 6, 2026. Unlike a traditional full-time CFO, Mushak will serve in a fractional capacity through his consulting firm LMAM.
Added in current filing · verify on EDGAR →
Mr. Mushak has been, and will remain, employed by LMAM and will be providing his services pursuant to the Consulting Agreement between the Company and LMAM. The material terms of the engagement are that the Company will pay Mr. Mushak $6,000 per month for the services rendered by Mr. Mushak.
The new CFO will be compensated $6,000 per month through a consulting agreement with his firm LMAM, rather than as a direct employee. This fractional arrangement may indicate cost management or a transitional CFO structure.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Mr. Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support.
Andriy Mushak brings 20 years of experience in SEC reporting and accounting compliance as a CPA and partner at LMAM Consulting Group. His background includes leading SEC reporting engagements and serving as Senior Manager at Baker Tilly US, LLP.
Event · Item 9.01 — Financial Statements and Exhibits
Telomir Pharmaceuticals entered into a consulting agreement with LMAM Consulting Group, LLC.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Consulting Agreement between Telomir Pharmaceuticals, Inc. LMAM Consulting Group, LLC
The company has entered into a consulting agreement with LMAM Consulting Group, LLC. The 8-K does not provide details about the scope, duration, or financial terms of the consulting arrangement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify